
Next-generation therapy overcomes limitations of other CAR-T
A new chimeric antigen receptor T cell (CAR-T) therapy has delivered highly promising results in treating patients with relapsed/refractory B-cell acute lymphoblastic leukaemia (r/r B-ALL). The FELIX clinical trial was led by researchers at University College London (UCL) and UCLH and sponsored by UCL spin-out Autolus Therapeutics. Read More













